The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.
 
Andreas Du Bois
Consulting or Advisory Role - AstraZeneca; Mundipharma; Pfizer; Pharmamar; Roche/Genentech
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Biogen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Fresenius (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hampton Medical Conferences (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Kendle (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Quintiles (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst); Sigma-Tau (Inst); Telik (Inst); TRM Oncology (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Proacta (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche
 
Gwenael Ferron
No Relationships to Disclose
 
Alexander Reuss
No Relationships to Disclose
 
Werner Meier
No Relationships to Disclose
 
Stefano Greggi
No Relationships to Disclose
 
Pernille Tina Jensen
No Relationships to Disclose
 
Frédéric Selle
No Relationships to Disclose
 
Frederic Guyon
No Relationships to Disclose
 
Christophe Pomel
No Relationships to Disclose
 
Fabrice Lecuru
No Relationships to Disclose
 
Rongyu Zang
No Relationships to Disclose
 
Elisabeth Avall-Lundqvist
Honoraria - Roche
Consulting or Advisory Role - AstraZeneca
 
Jae Weon Kim
No Relationships to Disclose
 
Jordi Ponce
No Relationships to Disclose
 
Francesco Raspagliesi
No Relationships to Disclose
 
Sadaf Ghaem-Maghami
No Relationships to Disclose
 
Alexander Reinthaller
Honoraria - Amgen; AstraZeneca; Novartis; PharmaMar; Roche
Travel, Accommodations, Expenses - AstraZeneca; Novartis; PharmaMar; Roche
 
Philipp Harter
Honoraria - AstraZeneca; Roche
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Sotio; Tesaro
Travel, Accommodations, Expenses - Medac
 
Jalid Sehouli
No Relationships to Disclose